Drug therapy of multiple myeloma--various factors influencing the effects of drugs
Yamazaki, K.
Gan no Rinsho. Japan Journal of Cancer Clinics 16(9): 889-895
1970
ISSN/ISBN: 0021-4949 PMID: 5528958 Document Number: 30377
Document emailed within 1 workday
Related Documents
Peest, D. 1998: Prognostic factors and standard therapy of multiple myeloma Praxis 87(25-26): 874-878Amira, C.O.; Okubadejo, N.U. 2007: Factors influencing non-compliance with anti-hypertensive drug therapy in Nigerians Nigerian Postgraduate Medical Journal 14(4): 325-329
Barlogie, B.; Alexanian, R. 1989: Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma Cancer Research 49(24 Pt 1): 7172-7175
Weber, D.M. 2003: Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation Oncology 17(6): 765-767
Spence, J.D. 1985: Effects of antihypertensive drugs on atherogenic factors: possible importance of drug selection in prevention of atherosclerosis Journal of Cardiovascular Pharmacology 7 Suppl. 2: S121-S125
Jagannath, S. 2009: New drugs in multiple myeloma and the significance of autologous stem cell transplants Clinical Advances in Hematology and Oncology: H&o 7(3): 178-179
Pick, A.I.; Tamir, R.; Vana, D.; Duczyminer-Kahana, M.; Weiss, H.; Lurie, H.; Dawidowich, J.; Meyerson, E.; Gelernter, I. 1990: Prognostic factors in multiple myeloma Harefuah 118(8): 437-442
Bladé, J.; Rozman, C.; Reverter, J.C.; Montserrat, E. 1988: Prognosis factors in multiple myeloma Revista Clinica Espanola 183(4): 215
Norcross, M.A. 1979: Factors influencing the use of veterinary drugs Journal of the American Veterinary Medical Association 174(5): 518-521
Teichmann, G.; Riethling, A.K. 1980: Side effects of drugs, individual hypertension therapy, and drug-taking behavior of patients Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 35(19): Suppl: 103-105
Alberts, D.S.; Durie, B.G.; Salmon, S.E. 1977: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics Cancer Treatment Reports 61(3): 381-388
Basit, A.; Siddiqui, N.; Hameed, A.; Muzaffar, N.; Athar, S. 2014: Factors affecting outcome of patients with multiple myeloma Journal of Ayub Medical College Abbottabad: Jamc 26(3): 376-379
Cid, E. 1974: Factors influencing the bioavailability of drugs in the form of tablets Pharmaceutica Acta Helvetiae 49(9-10): 285-292
Bladé, J.; Rozman, C. 1984: Multiple myeloma: analysis of prognostic factors and classification by stages Sangre 29(5): 918-926
Chavynchak, R.B.; Rekhtina, I.G. 2008: Prognostic factors in multiple myeloma complicated with renal failure Terapevticheskii Arkhiv 80(1): 84-88
Pasqualetti, P.; Colantonio, D.; Casale, R.; Lorenzetti, G.; Natali, G. 1989: Prognostic factors in multiple myeloma. Selection using multivariate analysis Recenti Progressi in Medicina 80(10): 543-546
Voigt, R.; Richter, M. 1984: Factors influencing the in vitro and in vivo liberation of drugs from hydrogels Die Pharmazie 39(9): 618-620
Avvisati, G.; Pulsoni, A.; Petrucci, M.T.; Tribalto, M. 1990: Therapy of multiple myeloma and its complications Recenti Progressi in Medicina 81(10): 642-650
Izumi, T. 2014: Novel targeted therapy in multiple myeloma Nihon Rinsho. Japanese Journal of Clinical Medicine 72(6): 1089-1093
Wang, Q.-x.; Yan, Y.-p.; Ji, Z.-h.; Ni, Q.-r.; Song, Y.-p.; Li, S.-t.; Xie, J.; Ren, J.-j.; Guo, L.; Dai, J.-q. 2013: Study on the quality of life and its related factors on patients with multiple myeloma Zhonghua Liu Xing Bing Xue Za Zhi 34(12): 1233-1236